Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA-positive metastatic castration-resistant prostate cancer MONTREAL, QC – Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful… Read More
Improved method for creating nucleoside analogues opens the door to discovering countless treatments for everything from cancer to viral diseases. By Adrianna MacPherson A team of researchers has found a… Read More
Proposed acquisition adds Nimble’s lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoimmune diseases where… Read More
Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original target Nomination of ZW209, a… Read More
OTTAWA, ON – The Stem Cell Network (SCN) is delighted to congratulate Dr. Michael Rudnicki and his team at The Ottawa Hospital Research Institute on their remarkable discovery of the… Read More
